JY1001

JY1001 (also known as JMKX007953) is an investigational, highly selective small molecule blocker of the voltage-gated sodium channel NaV1.8 (SCN10A) being developed by Jiminkexin (through its subsidiaries Jiyu Pharma and Zhejiang Hangyu Pharmaceutical) for the treatment of pain, including acute and chronic pain. NaV1.8 is primarily expressed in peripheral sensory neurons (dorsal root ganglions) and plays a critical role in the generation and transmission of pain signals. By selectively blocking NaV1.8, JY1001 aims to inhibit pain signal transmission at the source without affecting the central nervous system, thereby avoiding the side effects and addiction risks associated with opioids and NSAIDs. JY1001 is formulated as an intravenous injection and is currently undergoing Phase 1 clinical evaluation in healthy volunteers to assess its safety, tolerability, pharmacokinetics, and QTc effects.